Industry News

- Read more about New data demonstrate sustained long-term efficacy of OFEV®* on slowing disease progression and safety in patients with IPF
- Interim analysis of INPULSIS®-ON study shows: Beneficial effect of OFEV®* on slowing disease progression was maintained and the change from baseline in FVC was consistent over 2 years
- Long-term treatment with OFEV®* had a manageable safety and tolerability profile (mean exposure of 2.4 years, maximum exposure of more than 3 years)
- Commonly used concomitant medications, such as anti-acids or systemic steroids, do not influence the beneficial effect of OFEV®* on slowing disease progression
- Read more about Dr. Reddy’s Lab Introduce Generic Version of Nexium DR capsules in US market
- Read more about Pharma Companies get Innovative, use Indegene’s App for Apple Watch for Ethical Marketing and Reaching out to Doctors
(NewsVoir); Necessity is the mother of all invention. Pharmaceuticals industry just got innovative in reaching out to doctors with the latest app for Apple Watch under the Ethical Marketing norms. Developed by Indegene, the leading provider of healthcare solutions to the global pharmaceuticals industry, medical insurers and hospitals in the US, has developed the latest app for the Apple Watch for the healthcare industry to engage with doctors. This app augurs well for the Pharma industry already reeling under pressures of compliance norms for ethical marketing to doctors.
- Read more about Perrigo receive US FDA approval for generic BenzaClin topical gel
Perrigo Company plc, received US Food and Drug Administration (FDA) approval for the generic version of Valeant Pharmaceutical International Inc's BenzaClin topical gel.

[adsense:336x280:8701650588]
- Read more about B. Braun's Infusomat Space Pump get US FDA approval
B. Braun Medical Inc. (B.Braun), a leader in infusion therapy and pain management, has received 510(k) clearance for its second-generation, large-volume Infusomat Space Pump.
- Read more about European Union approved Praluent® (alirocumab) for the treatment of hypercholesterolemia
European Commission (EC) has granted marketing authorization for Praluent® (alirocumab) for the treatment of bad cholesterol, known as low-density lipoprotein (LDL) cholesterol, in certain adult patients with hypercholesterolemia. Praluent is the only EC-approved PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor that is available in two starting doses as a single 1-milliter (mL) injection (75 mg and 150 mg) once every two weeks, offering two levels of efficacy. Praluent will be available in a single-dose pre-filled pen that patients self-administer.
- Read more about Pfizer in US market launch Centrum VitaMints multivitamin tablets
Pfizer Consumer Healthcare launch Centrum VitaMints, a great-tasting and easy-to-take multivitamin in US Market. Centrum VitaMints is a refreshing and complete multivitamin that provides a more enjoyable experience for consumers to get essential nutrients, and joins other Centrum products to form one of the most comprehensive lines of multivitamins on the market.
- Read more about WORLD PHARMACISTS DAY Celebrations Proceedings in RIPER
World Pharmacists Day (SEPTEMBER 25, 2015)

The Indian Pharmaceutical Association (IPA) Anantapuramu Local Branch, with Head Office of Raghavendra Institute of Pharmaceutical Education & Research (RIPER), celebrated the World Pharmacist Day on September 15, 2015 (Friday).
- Read more about U.S. Food and Drug Administration noded to BMS's sBLA for untreated advanced melanoma
U.S. Food and Drug Administration (FDA) has accepted BMS's filing and review a supplemental Biologics License Application (sBLA) for the Opdivo (nivolumab)+Yervoy (ipilimumab) regimen to include clinical data from CheckMate -067, a landmark trial in patients with previously untreated advanced melanoma. The FDA also granted Priority Review for this application with a target action date of January 23, 2016.
- Read more about BMS and Moffitt Cancer Center collaborated to investigation of immuno-oncology therapeutics
Bristol-Myers Squibb Company (BMS) and Moffitt Cancer Center today announced that they have entered into a collaboration agreement as part of Bristol-Myers Squibb’s Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S. The I-O RPM program is a multi-institutional initiative with academic-based cancer centers focused on the clinical investigation of immuno-oncology therapeutics as potential treatment options for patients with high risk, poor prognostic cancers, defined as a rare population malignancy.